scholarly journals Pfetin as a Risk Factor of Recurrence in Gastrointestinal Stromal Tumors

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Hajime Orita ◽  
Tomoaki Ito ◽  
Tomoyuki Kushida ◽  
Mutsumi Sakurada ◽  
Hiroshi Maekawa ◽  
...  
Keyword(s):  
Predictive Model ◽  
Gastrointestinal Stromal Tumors ◽  
Abdominal Cavity ◽  
Univariate Analysis ◽  
Risk Of Recurrence ◽  
Stromal Tumors ◽  
Primary Gist ◽  
Grade Of Malignancy ◽  
Complete Tumor

Background. Despite complete resection of gastrointestinal stromal tumors (GIST), recurrent and/or metastatic disease occurs, often depending on the grade of malignancy. As such, markers are needed that accurately predict patients at high risk for recurrence. Previously our group reported Pfetin as a prognostic biomarker for GIST. In order to create an approach for predicting risk of recurrence, we incorporated Pfetin expression with clinicopathological data to produce a predictive model.Object. Forty-five patients with localized primary GIST were treated with complete gross surgical resection surgically at our institution between 1995 and 2010 were included. The majority of tumors originated in the stomach (38 cases), as well as small intestine (6 cases) and rectum (1 case).Method. (1) We performed retrospective analysis of the connection between Pfetin expression, clinicopathological data, and incidences of recurrence, using bivariate and multivariate analyses. (2) The reactivity of the monoclonal antibody against Pfetin was examined by immunohistochemistry.Pfetin. We have reported Pfetin, identified microarray technology, and compared between statistically different GISTs for good and poor prognoses and for prognostic marker.Results. There were 7 cases of recurrences. (1) By univariate analysis, tumor size, mitoses, exposure to abdominal cavity, and complete tumor removal predicted risk of recurrence. (2) Pfetin-negative cases were significantly related to recurrence (P= 0.002).Conclusions. This analysis demonstrates that lack of Pfetin expression is an additional predictor of recurrence in resected GIST. Further study may determine the role of this variable added to the current predictive model for selection of adjuvant therapy.

scholarly journals Clinical Overview of GIST and Its Latest Management by Endoscopic Resection in Upper GI: A Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Cicilia Marcella ◽  
Rui Hua Shi ◽  
Shakeel Sarwar
Keyword(s):  
Endoscopic Resection ◽  
Gastrointestinal Stromal Tumors ◽  
En Bloc Resection ◽  
Bloc Resection ◽  
En Bloc ◽  
Endoscopic Techniques ◽  
Stromal Tumors ◽  
Upper Gi ◽  
Risk Of Malignancy

Aims. To review the clinical presentation, diagnosis, assessment of risk of malignancy, and recent advances in management (mainly focusing on the role of endoscopic resection) of gastrointestinal stromal tumors (GISTs) in upper GI.Method. We searched Embase, Web of science, and PubMed databases from 1993 to 2018 by using the following keywords: “gastrointestinal stromal tumors,” “GIST,” “treatment,” and “diagnosis.” Additional papers were searched manually from references of the related articles.Findings. The improvement of endoscopic techniques in treating upper gastrointestinal subepithelial tumors especially gastrointestinal tumors has reduced the need for invasive surgery in patients unfit for surgery. Many studies have concluded that modified endoscopic treatments are effective and safe. These treatments permit minimal tissue resection, better dissection control, and high rates of en bloc resection with an acceptable rate of complications.

scholarly journals Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors

2018 ◽  
Author(s):  
Jen‑Shi Chen ◽  
Chun‑Nan Yeh ◽  
Chi‑Tung Cheng ◽  
Chueh‑Chuan Yen ◽  
Yen‑Yang Chen ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

scholarly journals The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors

2019 ◽  
Vol 22 (6) ◽  
pp. 1100-1108
Author(s):  
Yuki Koga ◽  
Masaaki Iwatsuki ◽  
Kohei Yamashita ◽  
Yuki Kiyozumi ◽  
Junji Kurashige ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Gastrointestinal Stromal Tumors ◽  
Predictive Marker ◽  
Stromal Tumors ◽  
Cell Cycle Regulator ◽  
A Cell

Gastrointestinal Stromal Tumors and Leiomyomas in the Dog: A Histopathologic, Immunohistochemical, and Molecular Genetic Study of 50 Cases

2003 ◽  
Vol 40 (1) ◽  
pp. 42-54 ◽  
Author(s):  
D. Frost ◽  
J. Lasota ◽  
M. Miettinen
Keyword(s):  
Smooth Muscle ◽  
Gastrointestinal Stromal Tumors ◽  
Smooth Muscle Actin ◽  
Abdominal Cavity ◽  
Clinical Signs ◽  
Muscle Actin ◽  
Molecular Genetic Study ◽  
Stromal Tumors ◽  
Pathologic Features ◽  
S 100

Fifty canine gastrointestinal (GI) mesenchymal tumors were examined to determine the occurrence of leiomyomas (LM) and GI stromal tumors and to compare their clinicopathologic features. Twenty-one tumors (42%) were histologically reclassified as gastrointestinal stromal tumors (GISTs) and 29 tumors (58%) as LMs on the basis of their histologic similarity with homologous human tumors. The GISTs occurred equally in males and females, with a mean age of 11 years (range 5–14 years). Five GISTs (24%) were associated with clinical signs and six (29%) had metastasis in liver or abdominal cavity. The GISTs occurred in large intestine (10, 48%), small bowel (six, 29%), stomach (four, 19%), and mesentery of small intestine (one, 5%). Histologically, they were highly cellular spindle, or less commonly epithelioid tumors with mitotic rates ranging from 0 to 19 per 10 HPF. Eleven tumors (52%) were positive for CD117 (KIT); seven (33%) were positive for smooth muscle actin but none for desmin and S-100 protein. Sequences of KIT exon 11, often mutated in human GISTs, were evaluated from four GISTs. Deletion of Try556-Lys557 coexisting with duplication of Gln555 in one case of GIST and T to C transition resulting in substitution of Pro for Leu575 in another were identified. The LMs occurred predominantly in males (82%) with a mean age of 11 years (range 8–17 years). Nine tumors (31%) had associated clinical signs. They occurred in the stomach (22, 76%), esophagus (four, 14%), and intestines (three, 10%); all were paucicellular, had no mitoses, and were composed of mature smooth muscle cells. Twenty-eight (97%) were positive for smooth muscle actin and 18(62%) for desmin but none for CD117 and S-100. Both GISTs and true LMs occur in the GI tract of dogs. Both tumors have distinctive pathologic features.

scholarly journals The Inside Mystery of Jejunal Gastrointestinal Stromal Tumor: A Rare Case Report and Review of the Literature

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
A. K. Dhull ◽  
V. Kaushal ◽  
R. Dhankhar ◽  
R. Atri ◽  
H. Singh ◽  
...  
Keyword(s):  
High Risk ◽  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Rare Case ◽  
Immunohistochemical Analysis ◽  
Resected Specimen ◽  
Stromal Tumors ◽  
Primary Gist ◽  
Large Size ◽  
Operative Findings

Gastrointestinal stromal tumors (GISTs) are malignant and rare form of soft tissue sarcoma of the digestive tract. The incidence of gastrointestinal stromal tumors is very low Kramer et al. 2005 Jejunal GISTs are extremely rare. Here we present a rare case of jejunal GIST with unusually large size at presentation. The patient presented with severe abdomen pain, exophytic growth, and dimorphic anemia. Surgical resection of the tumor was carried out, and operative findings revealed a 15 × 10 cm growth, arising from serosal surface of jejunum, at the antimesenteric surface. Diagnosis in this case was made by subjecting the resected specimen to immunohistochemical analysis. In view of large size of the resected tumor, and high-risk histopathological features, imatinib mesylate 400 mg once daily was given as adjuvant chemotherapy. Patient is asymptomatic without any evidence of tumor recurrence after six months of postoperative followup. Imatinib as such is recommended in metastatic, residual or recurrent cases of GISTs or which are surgically not removable; however, recent recommendations suggests the use of imatinib mesylate after radical surgery in high-risk cases, because it has shown a significant decrease in the recurrence rate, and the Food and Drug Administration (FDA) has also approved the use of imatinib as adjuvant therapy after complete resection of localized, primary GIST.

Abstract 08: Role of upfront genomic analysis of gastrointestinal stromal tumors to identify imatinib-insensitive or resistant cases

2016 ◽  
Author(s):  
Aleksander Chojecki ◽  
Rebecca A. Moss ◽  
Hua Zhong ◽  
Elizabeth Poplin ◽  
Ellen Ronnen ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Genomic Analysis ◽  
Stromal Tumors

scholarly journals Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Xiaodong Gao ◽  
Anwei Xue ◽  
Yong Fang ◽  
Ping Shu ◽  
Jiaqian Ling ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document